Investor Information

Company Information

Integumen is a vertically integrated business. It’s core skin and human testing technology is built on a clinical based eco-system. Collaboration partners in artificial intelligence, clinical research, medical device and life science contribute to the service management platform. This allows skin-care, health-care, nutritional, pharmaceutical manufacturers and cosmetic companies to test consumer products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

The Company’s own skin-care range of products and cannabinoid oils (CBD)  sources have been used to test the platform that combines data analytics with access to therapeutic operational expertise offering client solutions ranging from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our laboratory grown living human tissue (Labskin).

Country of Incorporation

Integumen plc is incorporated in England and Wales with Registration Number 10205396. Integumen plc has operations in Ireland and the UK, and its main country of operation is the UK.

Registered Office

Sand Hutton Applied Innovation Campus
Sand Hutton, York
North Yorkshire YO41 1LZ
United Kingdom

Head Office

19 Railway Road
Dalkey, Co. Dublin

Articles of Association

The Company’s Articles of Association can be downloaded here

Management and Board
See Below
Board of Directors

Anthony (“Tony”) Richardson, Non-Executive Chairman Tony is a Fellow of the Association of Chartered Certified Accountants. He co-founded Alltracel Pharmaceuticals Plc (“Alltracel”) in 1996. Alltracel was admitted to trading on AIM in 2001 and successfully made a number of acquisitions in the area of oral health before a trade sale in 2008 to Hemcon Medical Technologies Inc. Tony joined Venn Life Sciences in 2007 as non-executive Chairman. In 2010, he assumed the role of Chief Executive Officer and in that year Venn Life Sciences completed two acquisitions that provide the basis for the current business.

Gerard Brandon, Chief Executive Officer Gerard was appointed Director and CEO of Integumen in August 2018. Previously, he joined Cellulac Limited (Ireland) as its Chief Executive Officer in May 2012 and assumed the same role for Cellulac plc in October 2013. In 1996 he became founder and CEO of Alltracel Pharmaceuticals PLC, where he built a team that oversaw numerous patents granted on refined cellulose. Alltracel was admitted to trading on AIM in 2001. In 2004, he was appointed as a Managing Partner for Farmabrand Private Equity. In 2009, he was appointed as an Executive Consultant to Eplixo Limited. He is a Fellow of the Ryan Academy of Entrepreneurs in Dublin.

Camillus Glover, Chief of Finance and Operations Camillus was appointed Director and COO of Integumen in August 2018. on the 29th of August he took over as Chief Financial Officer. Previously, he joined Cellulac Limited (Ireland) as Chief Financial Officer in May 2012 and assumed the same role for Cellulac plc in October 2013. He is a member of the Institute of Chartered Accountants Ireland. In 2003, he joined Alltracel as Commercial Director and was appointed Chief Operations Officer in 2005 until it was acquired in 2008 by Hemcon Medical Technologies (“Hemcon”). Between 2009 and 2012, he was VP of Global Business Development for Hemcon prior to joining Cellulac.

Ross Andrews, Non-Executive Director Ross is a highly experienced corporate adviser with 30 years’ experience advising companies and management teams on public market transactions, largely in the UK but also in Europe, Australia, and Asia. He has worked with large corporates as well as numerous small, growing companies, providing advice on a range of equity capital matters, including IPOs, fundraisings, strategy, acquisitions, corporate governance and shareholder matters. Ross was a director and shareholder of Zeus Capital Limited until July 2015 when he formed RMA Consultancy Limited to undertake non-executive appointments or consultancy and project management roles within companies undergoing management change, external investment rounds or seeking a liquidity event through IPO or other exits.

Fionan (Fin) Murray, Group Sales Director Fin is the Founder of Rinocloud Limited. He is a seasoned sales executive with more than 30 years’ experience in worldwide distribution deals, selling complex software solutions into the multi-national corporate sectors in financial services, biotech, utilities and government departments. He is former CEO of LeT Systems Ltd and a senior executive at KBC Bank and Kindle Banking systems.


Shareholder Information

Securities in Issue

As at 2 May 2019, the number of securities in issue was 953,173,684

Significant Shareholders

As at 2 May 2019, shareholders holding more than 3% of the share capital of Integumen were:

Shareholder NameNo. of Ordinary Shares% of Existing Share Capital
Helium Rising Stars72,333,7237.59%
Cellulac plc38,205,1274.01%
Venn Life Science30,205,1273.15%
Tony Richardson*2,850,4140.30%
Gerard Brandon49,114,5015.15%
Ross Andrews2,238,4620.23%
Camillus Glover41,422,1944.35%
Fionan Murray86,783,0689.10%

* Tony Richardson is a director of Venn Life Sciences which owns Ordinary Shares in the Company


Shares not in public hands

As at 2 May 2019, 37.86% of the Company’s securities were not in public hands

Restrictions in transfer of securities

There are no restrictions on the transfer of Integumen’s securities

Other exchanges and trading platforms

Integumen plc has not applied or agreed to have its securities admitted or traded on any other exchanges or trading platforms

UK City Code on Takeovers and Mergers

Integumen plc is subject to the UK City Code on Takeovers and Mergers legislation

Page last updated 2 May 2019

Share Dealing Code
The Board has adopted a share dealing code consistent with Rule 21 of the AIM Rules for Companies and MAR to regulate dealings in the Ordinary Shares by Directors and any other applicable employees (as defined by the AIM Rules for Companies). The Directors consider that this share dealing code is appropriate for a company whose shares are admitted on AIM.

The Company will take proper steps to ensure compliance by the Directors and applicable employees with the terms of the share dealing code and the relevant provisions of the AIM Rules for Companies (including Rule 21).

Company Publications

Company Publications

Reports & Accounts

Integumen PLC Interim Report 2018 – download pdf version.
Integumen PLC Annual Report 2017 – download pdf version.
Integumen PLC Interim Report 2017 – download pdf version.
Integumen PLC Annual Report 2016 – download pdf version.

Circulars & Notices

EGM Circular & Proxy April 2019 – download pdf version.
EGM Circular & Proxy November 2018 – download pdf version.
AGM Circular & Proxy August 2018 – download pdf version.
EGM Circular & Proxy July 2018 – download pdf version.
EGM Circular & Proxy 2017 – download pdf version.

Company Documents

Admission Document The Company’s Admission Document can be downloaded here.

Articles of Association

The Company’s Articles of Association can be downloaded here.

AIM Rule 26

AIM Rule 26

The following information is disclosed for the purposes of compliance with AIM Rule 26. This information was last updated on 5 April 2017.

Description of the business see Company Information
Names of the Directors and biographical details see Board of Directors
Responsibilities of the Directors see Corporate Governance
Country of incorporation/operation see Company Information
Current Constitutional documents see Company Documents

Shareholder Information see Shareholder Information

  • Number of securities in issue
  • Significant shareholders
  • Shares not in public hands
  • Restrictions on transfer of securities
  • Other exchanges and trading platforms
  • UK City Code on Takeovers and Mergers

Corporate governance code see Corporate Governance
Company announcements made in the past 12 months see Regulatory News Service (RNS)
Financial Information see Reports and Accounts
Admission document and circulars see Company Documents
Advisers see Advisers

Nominated AdvisorBrokers
Spark Advisory Partners Limited
5 St John's Lane
London EC1M 4BH
Turner Pope Investments Limited
6th Floor – Becket House
36 Old Jewry
Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen B63 3DA
Solicitors to the Nominated Advisor
Addleshaw Goddard LLP
60 Chiswell Street
London EC1Y 4AG
Reporting Accountants
Jeffreys Henry LLP
Finsgate 5-7 Cranwood Street
London EC1V 9EE
Solicitors to Integumen
BPE Solicitors LLP
St James House
St James Square
Cheltenham GL50 3PR
Broker Notes

Turner Pope Note 29 April 2019 – download pdf version.

Latest Videos

Labskin enters clinical trials space

Completion of artificial intelligence  acquisition

Investor Event May 13 2019

Watch from 16:34 minutes in

Watch from 17 minutes in

Have an Investor Question?

Email us anytime

Or call — +44 (20) 3239 3716